AIMS: Gastro-resistant dimethyl fumarate (DMF) is an oral therapeutic indicated for the treatment of relapsing multiple sclerosis. Recent data suggest that a primary pharmacodynamic response to DMF treatment is activation of the nuclear factor (erythroid-derived 2)-like 2 (NRF2) pathway; however, the gene targets modulated downstream of NRF2 that contribute to DMF-dependent effects are poorly understood. RESULTS: Using wild-type and NRF2 knockout mice, we characterized DMF transcriptional responses throughout the brain and periphery to understand DMF effects in vivo and to explore the necessity of NRF2 in this process. Our findings identified tissue-specific expression of NRF2 target genes as well as NRF2-dependent and -independent gene regulation after DMF administration. Furthermore, using gene ontology, we identified common biological pathways that may be regulated by DMF and contribute to in vivo functional effects. INNOVATION: Together, these data suggest that DMF modulates transcription through multiple pathways, which has implications for the cytoprotective, immunomodulatory, and clinical properties of DMF. CONCLUSION: These findings provide further understanding of the DMF mechanism of action and propose potential therapeutic targets that warrant further investigation for treating neurodegenerative diseases. Antioxid. Redox Signal. 24, 1058-1071.
AIMS: Gastro-resistant dimethyl fumarate (DMF) is an oral therapeutic indicated for the treatment of relapsing multiple sclerosis. Recent data suggest that a primary pharmacodynamic response to DMF treatment is activation of the nuclear factor (erythroid-derived 2)-like 2 (NRF2) pathway; however, the gene targets modulated downstream of NRF2 that contribute to DMF-dependent effects are poorly understood. RESULTS: Using wild-type and NRF2 knockout mice, we characterized DMF transcriptional responses throughout the brain and periphery to understand DMF effects in vivo and to explore the necessity of NRF2 in this process. Our findings identified tissue-specific expression of NRF2 target genes as well as NRF2-dependent and -independent gene regulation after DMF administration. Furthermore, using gene ontology, we identified common biological pathways that may be regulated by DMF and contribute to in vivo functional effects. INNOVATION: Together, these data suggest that DMF modulates transcription through multiple pathways, which has implications for the cytoprotective, immunomodulatory, and clinical properties of DMF. CONCLUSION: These findings provide further understanding of the DMF mechanism of action and propose potential therapeutic targets that warrant further investigation for treating neurodegenerative diseases. Antioxid. Redox Signal. 24, 1058-1071.
Authors: Gerardo G Piroli; Allison M Manuel; Tulsi Patel; Michael D Walla; Liang Shi; Scott A Lanci; Jingtian Wang; Ashley Galloway; Pavel I Ortinski; Deanna S Smith; Norma Frizzell Journal: Mol Cell Proteomics Date: 2018-12-26 Impact factor: 5.911
Authors: Sriram Krishnamoorthy; Betty Pace; Dipti Gupta; Sarah Sturtevant; Biaoru Li; Levi Makala; Julia Brittain; Nancy Moore; Benjamin F Vieira; Timothy Thullen; Ivan Stone; Huo Li; William E Hobbs; David R Light Journal: JCI Insight Date: 2017-10-19
Authors: Lei Liu; Mary K Vollmer; Abdullah S Ahmad; Victoria M Fernandez; Hocheol Kim; Sylvain Doré Journal: Free Radic Biol Med Date: 2018-11-17 Impact factor: 7.376
Authors: Lei Liu; Mary K Vollmer; Marie G Kelly; Victoria M Fernandez; Tyler G Fernandez; Hocheol Kim; Sylvain Doré Journal: Mol Neurobiol Date: 2019-09-07 Impact factor: 5.590
Authors: Ayla Hoogendoorn; Thomas D Avery; Jiahe Li; Christina Bursill; Andrew Abell; Peter M Grace Journal: Trends Pharmacol Sci Date: 2021-02-19 Impact factor: 14.819
Authors: Anna Piovan; Raffaella Filippini; Giovanni Corbioli; Vanessa Dalla Costa; Elisabetta Maria Vittoria Giunco; Gianluca Burbello; Andrea Pagetta; Pietro Giusti; Morena Zusso Journal: Mol Neurobiol Date: 2021-03-21 Impact factor: 5.590